The European Commission Approves Astellas' VYLOY™ (zolbetuximab) with Chemotherapy for Advanced Stomach and Gastroesophageal Junction Cancer.

The U.S. Food and Drug Administration has greenlit Miplyffa (arimoclomol), an oral drug designed for managing Niemann-Pick disease type C (NPC).

OPUVIZ has received a recommendation for approval for adult patients in the treatment of neovascular (wet) age-related macular degeneration (AMD).

Tolebrutinib showed a 31% delay in the onset of confirmed disability progression in a phase 3 study of non-relapsing secondary progressive multiple sclerosis.

Tectonic Therapeutic Shares Positive Safety, Tolerability, and PK/PD Phase 1a Results for Lead Candidate TX45.

siRNA and ASO are two nucleic acid-based gene silencing technologies that achieve precise regulation of gene expression by complementary pairing with specific mRNA sequences.

Trishula Therapeutics' Phase 1 trial of TTX-030 shows encouraging results for first-line treatment of metastatic pancreatic cancer.

the Danish pharmaceutical company Zealand Pharma announced clinical Phase 1 data for its long-acting amylin analogue, Petrelintide, which is being studied for weight management.

Beacon Therapeutics Shares 36-Month Interim Data from HORIZON Phase I/2 Trial of AGTC-501 for XLRP Patients.

Amylin is a pancreatic peptide consisting of 37 amino acids that is co-stored and co-secreted with insulin in response to nutrient intake.

RYBREVANT® (amivantamab-vmjw) with standard care now approved in the U.S. as the sole targeted treatment reducing disease progression risk by over 50% for second-line EGFR-mutated advanced lung cancer.

Sep 24th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.